Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms

Zhang,Wan; Pelicano,Helene; Yin,Ran; Zeng,Junyi; Wen,Tong; Ding,Lu; Huang,Ruibin

doi:10.3892/mmr.2015.4364

Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms

Authors:
- Wan Zhang
- Helene Pelicano
- Ran Yin
- Junyi Zeng
- Tong Wen
- Lu Ding
- Ruibin Huang
View Affiliations

Affiliations: Department of Leukemia, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA, Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: September 25, 2015 https://doi.org/10.3892/mmr.2015.4364
Pages: 7374-7388
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, and is currently incurable due to drug resistance. A previous study indicated that the redox interaction between bone marrow stromal cells and leukemia cells profoundly affected CLL cell viability and drug response. The present study aimed to further investigate the effect of the redox interaction on drug resistance of CLL cells in the bone marrow microenvironment, and to assess a novel redox-mediated strategy to eliminate stromal-protected CLL cells, and thus to achieve maximum therapeutic efficacy of antileukemic drugs. Histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) is a potent novel anticancer agent, however, it exerts limited activity in patients with CLL. The results of the present study demonstrated that SAHA facilitated stromal‑mediated glutathione upregulation in the CLL cells, contributing to drug resistance. The addition of β‑phenylethyl isothiocyanate (PEITC) induced severe depletion of stromal and SAHA‑upregulated glutathione, enhanced SAHA‑mediated reactive oxygen species accumulation in the CLL cells and caused oxidation of mitochondrial cardilopin, leading to substantial cell death. The results further demonstrated that stromal cells and SAHA markedly upregulated antiapoptotic protein expression levels of myeloid cell leukemia 1 (Mcl1) in CLL the cells. By inducing protein deglutathionylation and degradation, PEITC suppressed the expression of Mcl1 in co‑cultured CLL cells, and increased SAHA sensitivity. The combination of SAHA and PEITC enabled the induction of marked apoptosis of CLL cells co‑cultured with bone marrow stromal cells. The present study provided a preclinical rationale, which warrants further clinical investigation for the potential use of SAHA/PEITC as a novel combination treatment strategy for CLL.

View Figures

View References

1	Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL;, Rai KR, Ferrarini M and Kipps TJ: Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003:153–175. 2003. View Article : Google Scholar
2	Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 20:479–498. 2007. View Article : Google Scholar : PubMed/NCBI
3	Chiorazzi N, Rai KR and Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med. 352:804–815. 2005. View Article : Google Scholar : PubMed/NCBI
4	Munk Pedersen I and Reed J: Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma. 45:2365–2372. 2004. View Article : Google Scholar : PubMed/NCBI
5	Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, Bruck M, Brown R and Canellakis ZN: Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood. 80:2038–2043. 1992.PubMed/NCBI
6	Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH and Kerr JF: Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol. 71:343–350. 1989. View Article : Google Scholar : PubMed/NCBI
7	Zhou Y, Hileman EO, Plunkett W, Keating MJ and Huang P: Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 101:4098–4104. 2003. View Article : Google Scholar : PubMed/NCBI
8	Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ and Huang P: Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 14:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
10	Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene. 26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
11	Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63:3637–3645. 2003.PubMed/NCBI
12	Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, et al: Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood. 116:2732–2741. 2010. View Article : Google Scholar : PubMed/NCBI
13	O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 24:166–173. 2006. View Article : Google Scholar
14	Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D and Lagneaux L: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica. 95:1136–1143. 2010. View Article : Google Scholar : PubMed/NCBI
15	Pérez-Perarnau A, Coll-Mulet L, Rubio-Patiño C, Iglesias-Serret D, Cosialls AM, González-Gironès DM, de Frias M, de Sevilla AF, de la Banda E, Pons G and Gil J: Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics. 6:1228–1235. 2011. View Article : Google Scholar : PubMed/NCBI
16	Abou-Nassar K and Brown JR: Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 8:886–895. PubMed/NCBI
17	Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, et al: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 147:507–514. 2009. View Article : Google Scholar : PubMed/NCBI
18	Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, et al: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 105:959–967. 2005. View Article : Google Scholar
19	Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S and Rai KR: National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:4990–4997. 1996.PubMed/NCBI
20	Huang P, Sandoval A, Van Den Neste E, Keating MJ and Plunkett W: Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 14:1405–1413. 2000. View Article : Google Scholar : PubMed/NCBI
21	Iverson SL and Orrenius S: The cardiolipincytochrome c interaction and the mitochondrial regulation of apoptosis. Arch Biochem Biophys. 423:37–46. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zenkov NK, Menshchikova EB and Tkachev VO: Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc). 78:19–36. 2013. View Article : Google Scholar
23	Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, et al: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 112:1912–1922. 2008. View Article : Google Scholar : PubMed/NCBI
24	Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, et al: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 175:913–923. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
26	Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76–86. 1999. View Article : Google Scholar : PubMed/NCBI
27	Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M and Talalay P: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA. 99:11908–11913. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lu SC: Regulation of glutathione synthesis. Curr Top Cell Regul. 36:95–116. 2000. View Article : Google Scholar : PubMed/NCBI
29	Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 16:444–454. 2002. View Article : Google Scholar : PubMed/NCBI
30	Balakrishnan K, Burger JA, Wierda WG and Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 113:149–153. 2009. View Article : Google Scholar :
31	Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, et al: Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction and miR34a in a prospective clinical trial. Blood. 114:2589–2597. 2009. View Article : Google Scholar : PubMed/NCBI
32	Caligaris-Cappio F: Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 4:5–21. 2000. View Article : Google Scholar
33	Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004. View Article : Google Scholar : PubMed/NCBI
34	Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y and Ohyashiki K: Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: A potential treatment for BCR-ABL-positive leukemia. PLoS One. 9:e890802014. View Article : Google Scholar : PubMed/NCBI
35	Thurn KT, Thomas S, Moore A and Munster PN: Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7:263–283. 2011. View Article : Google Scholar : PubMed/NCBI
36	Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101:3236–3239. 2003. View Article : Google Scholar
37	He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM and Pandolfi PP: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 108:1321–1330. 2001. View Article : Google Scholar : PubMed/NCBI
38	VanderMolen KM, McCulloch W, Pearce CJ and Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 64:525–531. 2011. View Article : Google Scholar
39	Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 111:1060–1066. 2008. View Article : Google Scholar
40	Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL: The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
41	Bannai S: Transport of cystine and cysteine in mammalian cells. Biochim Biophys Acta. 779:289–306. 1984. View Article : Google Scholar : PubMed/NCBI
42	Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood. 91:3379–3389. 1998.PubMed/NCBI
43	Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F and Wang X: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
44	Adams KW and Cooper GM: Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem. 282:6192–6200. 2007. View Article : Google Scholar : PubMed/NCBI
45	Inoue S, Walewska R, Dyer MJ and Cohen GM: Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia. 22:819–825. 2008. View Article : Google Scholar : PubMed/NCBI
46	Ghezzi P: Regulation of protein function by glutathionylation. Free Radic Res. 39:573–580. 2005. View Article : Google Scholar : PubMed/NCBI
47	An X, Schulz VP, Li J, Wu K, Liu J, Xue F, Hu J, Mohandas N and Gallagher PG: Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood. 123:3466–3477. 2014. View Article : Google Scholar : PubMed/NCBI